220 related articles for article (PubMed ID: 35689207)
1. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak M; Tucker E; Dorel M; Winkler A; McGearey A; Rodriguez-Fos E; da Costa BM; Barker K; Fyle E; Calton E; Eising S; Ober K; Hughes D; Koutroumanidou E; Carter P; Stankunaite R; Proszek P; Jain N; Rosswog C; Dorado-Garcia H; Molenaar JJ; Hubank M; Barone G; Anderson J; Lang P; Deubzer HE; Künkele A; Fischer M; Eggert A; Kloft C; Henssen AG; Boettcher M; Hertwig F; Blüthgen N; Chesler L; Schulte JH
Mol Cancer; 2022 Jun; 21(1):126. PubMed ID: 35689207
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
3. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
[TBL] [Abstract][Full Text] [Related]
4. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors.
Westerhout EM; Hamdi M; Stroeken P; Nowakowska NE; Lakeman A; van Arkel J; Hasselt NE; Bleijlevens B; Akogul N; Haneveld F; Chan A; van Sluis P; Zwijnenburg D; Volckmann R; van Noesel CJM; Adameyko I; van Groningen T; Koster J; Valentijn LJ; van Nes J; Versteeg R
Cancer Res; 2022 Feb; 82(3):484-496. PubMed ID: 34853072
[TBL] [Abstract][Full Text] [Related]
6. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
7. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
[TBL] [Abstract][Full Text] [Related]
8. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma.
Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
[TBL] [Abstract][Full Text] [Related]
9. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract][Full Text] [Related]
10. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
Tucker ER; Jiménez I; Chen L; Bellini A; Gorrini C; Calton E; Gao Q; Che H; Poon E; Jamin Y; Martins Da Costa B; Barker K; Shrestha S; Hutchinson JC; Dhariwal S; Goodman A; Del Nery E; Gestraud P; Bhalshankar J; Iddir Y; Saberi-Ansari E; Saint-Charles A; Geoerger B; Marques Da Costa ME; Pierre-Eugène C; Janoueix-Lerosey I; Decaudin D; Nemati F; Carcaboso AM; Surdez D; Delattre O; George SL; Chesler L; Tweddle DA; Schleiermacher G
Clin Cancer Res; 2023 Apr; 29(7):1317-1331. PubMed ID: 36602782
[TBL] [Abstract][Full Text] [Related]
12.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
13. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
Tan DS; Thomas M; Kim DW; Szpakowski S; Urban P; Mehra R; Chow LQM; Sharma S; Solomon BJ; Felip E; Camidge DR; Vansteenkiste J; Petruzzelli L; Pantano S; Shaw AT
Lung Cancer; 2022 Jan; 163():7-13. PubMed ID: 34890832
[TBL] [Abstract][Full Text] [Related]
14. Dual
Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
[No Abstract] [Full Text] [Related]
15. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Berko ER; Witek GM; Matkar S; Petrova ZO; Wu MA; Smith CM; Daniels A; Kalna J; Kennedy A; Gostuski I; Casey C; Krytska K; Gerelus M; Pavlick D; Ghazarian S; Park JR; Marachelian A; Maris JM; Goldsmith KC; Radhakrishnan R; Lemmon MA; Mossé YP
Nat Commun; 2023 May; 14(1):2601. PubMed ID: 37147298
[TBL] [Abstract][Full Text] [Related]
16. Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
Redaelli S; Ceccon M; Zappa M; Sharma GG; Mastini C; Mauri M; Nigoghossian M; Massimino L; Cordani N; Farina F; Piazza R; Gambacorti-Passerini C; Mologni L
Cancer Res; 2018 Dec; 78(24):6866-6880. PubMed ID: 30322862
[TBL] [Abstract][Full Text] [Related]
17. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults.
Stiefel J; Kushner BH; Roberts SS; Iglesias-Cardenas F; Kramer K; Modak S
JCO Precis Oncol; 2023 Aug; 7():e2300138. PubMed ID: 37561984
[TBL] [Abstract][Full Text] [Related]
19. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
20. Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
